IsoRay Medical, Inc.   Report issue

For profit Phase 2
Founded: Richland WA United States (2004)
Status: Acquired by Viewpoint Molecular Targeting (2022)

Organization Overview

First Clinical Trial
2020
NCT04340258
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Mergers & Acquisitions

Historical Acquisition Tree

Alternative names

IsoRay Medical, Inc.